KR19990082506A - 염소의 간으로부터 분리한 뉴클레오티드 서열 - Google Patents
염소의 간으로부터 분리한 뉴클레오티드 서열 Download PDFInfo
- Publication number
- KR19990082506A KR19990082506A KR1019980706239A KR19980706239A KR19990082506A KR 19990082506 A KR19990082506 A KR 19990082506A KR 1019980706239 A KR1019980706239 A KR 1019980706239A KR 19980706239 A KR19980706239 A KR 19980706239A KR 19990082506 A KR19990082506 A KR 19990082506A
- Authority
- KR
- South Korea
- Prior art keywords
- sequence
- cdna
- liver
- goat
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004185 liver Anatomy 0.000 title abstract description 14
- 241000283707 Capra Species 0.000 title abstract description 11
- 239000002773 nucleotide Substances 0.000 title description 7
- 125000003729 nucleotide group Chemical group 0.000 title description 7
- 239000012634 fragment Substances 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 abstract description 22
- 101710164418 Movement protein TGB2 Proteins 0.000 abstract description 9
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 abstract description 9
- 231100000433 cytotoxic Toxicity 0.000 abstract description 2
- 230000001472 cytotoxic effect Effects 0.000 abstract description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 101710088758 23kDa protein Proteins 0.000 description 1
- 241000283705 Capra hircus Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000931108 Mus musculus DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Basic Packing Technique (AREA)
- Containers And Plastic Fillers For Packaging (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI000264A IT1282608B1 (it) | 1996-02-13 | 1996-02-13 | Sequenza oligonocleotidica da fegato di capra |
| ITMI96A000264 | 1996-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR19990082506A true KR19990082506A (ko) | 1999-11-25 |
Family
ID=11373242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980706239A Ceased KR19990082506A (ko) | 1996-02-13 | 1997-02-11 | 염소의 간으로부터 분리한 뉴클레오티드 서열 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6107474A (en:Method) |
| JP (1) | JP2000504578A (en:Method) |
| KR (1) | KR19990082506A (en:Method) |
| AU (1) | AU715178B2 (en:Method) |
| CA (1) | CA2246223A1 (en:Method) |
| GB (1) | GB2325466B (en:Method) |
| IL (1) | IL125737A0 (en:Method) |
| IT (1) | IT1282608B1 (en:Method) |
| LT (1) | LT4481B (en:Method) |
| WO (1) | WO1997030154A1 (en:Method) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1284524B1 (it) * | 1996-09-13 | 1998-05-21 | Zetesis Spa | Uso di proteine come agenti anti-retrovirali |
| US20010014471A1 (en) * | 1999-04-15 | 2001-08-16 | Vytautas Naktinis | Recombinant protein and its use in therapy and diagnostics |
| ITMI20010762A1 (it) * | 2001-04-10 | 2002-10-10 | Zetesis Spa | Uso della proteina uk114 o di suoi frammenti per il trattamento e la prevenzione dello shock endotossico |
| ITMI20010761A1 (it) * | 2001-04-10 | 2002-10-10 | Zetesis Spa | Uso della proteina uk114 per il trattamento e la prevenzione dell'epatite cronica attiva |
| IT201600127428A1 (it) * | 2016-12-16 | 2018-06-16 | Cusani Alberto Bartorelli | Nuova proteina ricombinante uk 114 in forma stabile polimerica per uso nella terapia, nella diagnostica e nella prevenzione di neoplasie maligne |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1244879B (it) * | 1990-12-11 | 1994-09-12 | Alberto Bartorelli | Estratti da tessuti animali, utili in terapia e in diagnostica. |
| IT1270618B (it) * | 1994-07-14 | 1997-05-07 | Zetesis Spa | Proteine ad attivita' antitumorale |
-
1996
- 1996-02-13 IT IT96MI000264A patent/IT1282608B1/it active IP Right Grant
-
1997
- 1997-02-11 KR KR1019980706239A patent/KR19990082506A/ko not_active Ceased
- 1997-02-11 AU AU16024/97A patent/AU715178B2/en not_active Ceased
- 1997-02-11 US US09/125,265 patent/US6107474A/en not_active Expired - Fee Related
- 1997-02-11 IL IL12573797A patent/IL125737A0/xx unknown
- 1997-02-11 JP JP9528967A patent/JP2000504578A/ja active Pending
- 1997-02-11 WO PCT/EP1997/000611 patent/WO1997030154A1/en not_active Application Discontinuation
- 1997-02-11 CA CA002246223A patent/CA2246223A1/en not_active Abandoned
- 1997-02-11 GB GB9817574A patent/GB2325466B/en not_active Expired - Fee Related
-
1998
- 1998-08-19 LT LT98-116A patent/LT4481B/lt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GB2325466B (en) | 2000-03-22 |
| LT4481B (lt) | 1999-03-25 |
| WO1997030154A1 (en) | 1997-08-21 |
| LT98116A (en) | 1999-01-25 |
| ITMI960264A1 (it) | 1997-08-13 |
| IT1282608B1 (it) | 1998-03-31 |
| IL125737A0 (en) | 1999-04-11 |
| US6107474A (en) | 2000-08-22 |
| GB9817574D0 (en) | 1998-10-07 |
| GB2325466A (en) | 1998-11-25 |
| AU715178B2 (en) | 2000-01-20 |
| ITMI960264A0 (en:Method) | 1996-02-13 |
| HK1016217A1 (en) | 1999-10-29 |
| JP2000504578A (ja) | 2000-04-18 |
| AU1602497A (en) | 1997-09-02 |
| CA2246223A1 (en) | 1997-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Furutani et al. | Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method | |
| JP4350815B2 (ja) | 変性キメラｄｎａポリメラーゼ | |
| EP0824598B1 (fr) | METHODE DE COUPLAGE SPECIFIQUE DE LA COIFFE DE L'EXTREMITE 5' D'UN FRAGMENT D'ARNm ET PREPARATION D'ARNm ET D'ADNc COMPLET | |
| EP1130094A3 (en) | Primers for synthesizing full length cDNA clones and their use | |
| RU99118585A (ru) | Отбор белков с использованием рнк-пептидных гибридов | |
| CA2071969A1 (en) | Hybrid molecules having translocation region and cell-binding region | |
| AU604003B2 (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
| KR19990082506A (ko) | 염소의 간으로부터 분리한 뉴클레오티드 서열 | |
| Wada et al. | Representational difference analysis of cDNA of genes expressed in embryonic kidney | |
| CA1299508C (en) | Human pancreatic elastase i | |
| JPH05502789A (ja) | ムチンヌクレオチド | |
| EP0157604B1 (en) | Porcine pancreatic elastase | |
| JPH02262594A (ja) | ポリペプチドおよびその製造法 | |
| Wosnick et al. | Total chemical synthesis and expression in Escherichia coli of a maize glutathione-transferase (GST) gene | |
| US5324715A (en) | Protein for inhibiting collagen-stimulated platelet aggregation | |
| EP0391957A1 (en) | A METHOD OF SIMULTANEOUSLY PRODUCING A LARGE NUMBER OF Leu?17 -VIP-ANALOGS AND NEW Leu?17 -VIP-ANALOGS | |
| Zhang et al. | cDNA sequences of variant forms of human placenta diamine oxidase | |
| US5321010A (en) | Proteins for inhibiting adhesion of platelets to collagen | |
| Shibuya et al. | The coding sequence of the bovine ferrochelatase gene | |
| EP0135347A1 (en) | Human renin and cDNA encoding therefor | |
| Graf et al. | Mitochondrial import of rat pre-ornithine transcarbamylase: accurate processing of the precursor form is not required for uptake into mitochondria, nor assembly into catalyticaUy active enzyme | |
| CA2228378A1 (en) | Cytidine deaminase cdna as a positive selectable marker for gene transfer, gene therapy and protein synthesis | |
| US5830656A (en) | Detecting the expression of the catr1 gene in squamous cell carcinoma | |
| Cooper et al. | Degenerate oligonucleotide sequence-directed cross-species PCR cloning of the BCP 54/ALDH 3 cDNA: priming from inverted repeats and formation of tandem primer arrays. | |
| JPH0937779A (ja) | ユビキチン結合酵素Ｅ２およびそれをコードするヒトｃＤＮＡ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 19980812 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20020208 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040130 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20040611 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040130 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |